cis-4-(1,1-dimethylethoxy)-L-proline

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: cis-4-(1,1-dimethylethoxy)-L-proline
• 英文别名: 4-t-Butoxy proline；(2S)-4-[(2-methylpropan-2-yl)oxy]pyrrolidine-2-carboxylic acid
• 化学式: C₉H₁₇NO₃
• 分子量: 187.239
• InChiKey: XTQZONYRNXFGCY-MLWJPKLSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.8
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  cis-4-(1,1-dimethylethoxy)-L-proline 、 3-乙酰硫基-2-甲基丙酰氯 、 二环己胺 在 碳酸氢钠 作用下， 以 乙醇 、 水 、 乙酸乙酯 、 乙腈 为溶剂， 生成 1-[D-3-(acetylthio)-2-methyl-1-oxopropyl]-cis-4-(1,1-dimethylethoxy)-L-proline
  参考文献：
  名称：

  Mercaptoacyl derivatives of substituted prolines

  摘要：

  新的取代脯氨酸巯基酰衍生物具有一般公式##STR1##，可用作降压剂。

  公开号：

  US04316906A1

文献信息

• Novel lincomycin derivatives possessing antimicrobial activity
  申请人：Lewis G. Jason

  公开号：US20050043248A1

  公开（公告）日：2005-02-24

  Novel lincomycin derivatives are disclosed. These lincomycin derivatives exhibit antibacterial activity. The compounds of the subject invention may exhibit potent activities against bacteria, including gram positive organisms, and may be useful antimicrobial agents. Methods of synthesis and of use of the compounds are also disclosed.

  新型的林可霉素衍生物被披露。这些林可霉素衍生物表现出抗菌活性。本发明的化合物可能对细菌，包括革兰氏阳性生物，表现出强效活性，并且可能是有用的抗微生物药剂。该化合物的合成和使用方法也被披露。
• Novel lincomycin derivatives possessing antibacterial activity
  申请人：Lewis G. Jason

  公开号：US20050215488A1

  公开（公告）日：2005-09-29

  Novel lincomycin derivatives are disclosed. These lincomycin derivatives exhibit antibacterial activity. The compounds of the subject invention may exhibit potent activities against bacteria, including Gram positive organisms, and may be useful antimicrobial agents. Methods of synthesis and of use of the compounds are also disclosed.

  新型的林可霉素衍生物已被披露。这些林可霉素衍生物表现出抗菌活性。本发明的化合物可能对细菌，包括革兰氏阳性生物，表现出强效活性，并可能是有用的抗微生物药剂。该化合物的合成和使用方法也已被披露。
• Process for producing optically active beta-trifluoromethyl-beta-hydroxycarbonyl compound
  申请人：Funabiki Kazumasa

  公开号：US20050119507A1

  公开（公告）日：2005-06-02

  The present invention provides a process for producing an optically active β-trifluoromethyl-β-hydroxycarbonyl compound represented by formula (3): comprising a step of reacting a fluoral equivalent represented by formula (1): with a carbonyl compound represented by formula (2): in the presence of an optically active amino acid or a derivative thereof.

  本发明提供了一种制备光学活性的β-三氟甲基-β-羟基羰基化合物的方法，该化合物由式（3）表示，包括在光学活性氨基酸或其衍生物的存在下，将由式（1）表示的芳醛等效物与由式（2）表示的羰基化合物反应的步骤。
• Substituted n-arylsulfonyl-proline derivatives as potent cell adhesion inhibitors
  申请人：——

  公开号：US20040102478A1

  公开（公告）日：2004-05-27

  Compounds of formula (I) are antagonists of VLA-4 and/or alpha4/beta7, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of AIDS-related dementia, allergic conjunctivitis, allergic rhinitis, Alzheimer's disease, asthma, atherosclerosis, autologous bone marrow transplantation, certain types of toxic and immune-based nephritis, contact dermal hypersensitivity, inflammatory bowel disease including ulcerative colitis and Crohn's disease, inflammatory lung diseases, inflammatory sequelae of viral infections, meningitis, multiple sclerosis, multiple myeloma, myocarditis, organ transplantation, psoriasis, pulmonary fibrosis, restenosis, rhinitis, rheumatoid arthritis, septic arthritis, stroke, tumor metastasis, uveititis, and type I diabetes.

  公式（I）的化合物是VLA-4和/或alpha4/beta7的拮抗剂，因此可用于抑制或预防细胞黏附和细胞黏附介导的病理过程。这些化合物可以制成药物组合物，并适用于治疗艾滋病相关痴呆症、过敏性结膜炎、过敏性鼻炎、阿尔茨海默病、哮喘、动脉粥样硬化、自体骨髓移植、某些类型的毒性和免疫性肾炎、接触性皮肤过敏、炎症性肠病，包括溃疡性结肠炎和克隆病、炎症性肺部疾病、病毒感染的炎症后遗症、脑膜炎、多发性硬化症、多发性骨髓瘤、心肌炎、器官移植、银屑病、肺纤维化、再狭窄、鼻炎、类风湿性关节炎、败血性关节炎、中风、肿瘤转移、葡萄膜炎和1型糖尿病的治疗。
• Cyclic tetrapeptides and therapeutic applications thereof
  申请人：LODZ UNIVERSITY OF TECHNOLOGY

  公开号：US10238713B2

  公开（公告）日：2019-03-26

  There are provided compounds of formula I: wherein k, m, n, p, R, R′, R″, R′″, R3, R4, R7 and R8 are as defined in the application. Other embodiments are also disclosed.

  提供了式 I 的化合物： 其中 k、m、n、p、R、R′、R″、R′″、R3、R4、R7 和 R8 如本申请中所定义。还公开了其他实施例。